Is there a role for earlier use of combination therapy?
As the global population ages and cardiovascular risk factors rise, we can expect a continued increase in atherosclerotic disease. Low-density lipoprotein cholesterol (LDL-C) reduction is a cornerstone of cardiovascular risk reduction with strong, causal evidence indicating that the greatest benefit...
Main Authors: | Shruti Revankar, Jong Kun Park, Priyanka Satish, Anandita Agarwala |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | American Journal of Preventive Cardiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667724000072 |
Similar Items
-
Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database
by: Dimitrios Terentes-Printzios, et al.
Published: (2024-06-01) -
The Paradoxical Association of Lipids with Survival and Walking Ability of Hip Fractures in Geriatric Patients After Surgery: A 1-Year Follow-Up Study
by: Zhao Z, et al.
Published: (2023-08-01) -
Editorial: New and emerging lipid-lowering therapies for reducing cardiovascular risk: beyond statins
by: Fei Luo, et al.
Published: (2024-01-01) -
Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review
by: Vera N. Larina, et al.
Published: (2023-04-01) -
Concordance of LDL-C Estimating Equations with Direct Enzymatic Measurement in Diabetic and Prediabetic Subjects
by: Serkan Bolat, et al.
Published: (2023-05-01)